Analytical Data
-
基因名
CD20/MS4A1
- Application
-
别名
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11836
-
表达区间
M1-P297
-
分子量
43 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD20, also known as MS4A1, is a transmembrane protein predominantly expressed on the surface of B cells, playing a crucial role in B cell development, activation, and differentiation. As a key target in the treatment of various hematological malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, CD20 serves as a potent biomarker for therapeutic interventions, including monoclonal antibody therapies like Rituximab. The recombinant protein form of CD20/MS4A1 has garnered significant attention in recent research, as it facilitates the understanding of the structure-function relationship of this protein and aids in the development of targeted therapies. Production of recombinant CD20/MS4A1 enables the exploration of its interactions with immune cells, the elucidation of its signaling pathways, and the assessment of its potential as an antigen for vaccine development. Moreover, the study of this recombinant protein assists in overcoming clinical challenges associated with CD20-targeted therapies, such as tumor resistance and heterogeneity. As a result, ongoing research aims to enhance therapeutic efficacy and identify novel approaches for B cell malignancies, ultimately improving patient outcomes in oncology.
